Two XPS™ to Florida

Two clinics in Florida have recently signed XPS™ agreements. It is estimated
that delivery of XPS™ to these two clinics will take place in March.
XVIVO Perfusion’s XPS™ and STEEN Solution™ are the only approved products in the
USA for evaluation of marginal lungs before lung transplantation. The products
enable more lungs to be used for transplantation, which means that more patients
with severe lung disease are given a higher quality and longer life. Leading
clinics in the USA have obtained good clinical results when using XPS™.

Florida is one of the states in the USA with the highest population count and is
ranked among the top five regarding the number of lung transplants performed in
the USA. The two clinics that have each ordered an XPS™ account for
approximately half of Florida’s lung transplants.

“We are very pleased that EVLP using XPS™ and STEEN Solution™ has made a
breakthrough in Florida, which is one of the states in the USA that perform the
most lung transplants. Naturally, we are particularly pleased that this has
occurred at two clinics at the same time,” says Magnus Nilsson, CEO of XVIVO
Perfusion.

March 19, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on March 19, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com